跳至主要内容
临床试验/NCT06409182
NCT06409182
已完成
不适用

A Prospective Pilot Study to Evaluate the Diagnostic Performance of a Wireless Sensor Capsule in Detection of Upper Gastrointestinal Bleeding

Chinese University of Hong Kong2 个研究点 分布在 1 个国家目标入组 30 人2023年12月19日
适应症UGI Bleed
干预措施Hemopill

概览

阶段
不适用
干预措施
Hemopill
疾病 / 适应症
UGI Bleed
发起方
Chinese University of Hong Kong
入组人数
30
试验地点
2
主要终点
Area under the ROC curve
状态
已完成
最后更新
10天前

概览

简要总结

It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).

详细描述

It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).

注册库
clinicaltrials.gov
开始日期
2023年12月19日
结束日期
2024年12月30日
最后更新
10天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

责任方
Principal Investigator
主要研究者

Louis Ho Shing Lau

Assistant Professor

Chinese University of Hong Kong

入排标准

入选标准

  • Subjects are eligible if:
  • They have symptoms and signs of suspected UGIB (melena, per rectal bleeding, coffee ground vomiting, history of hematemesis);
  • They will undergo OGD within 24 hours;
  • Written consent obtained.

排除标准

  • Subjects will be excluded from the study if they have any of the followings:
  • Contraindications for OGD (e.g. respiratory failure, suspected perforation);
  • Contraindications for capsule endoscopy (e.g. known gastrointestinal obstruction or stricture, severe dysphagia, impaired consciousness);
  • Cardiac pacemaker or implanted electromedical devices;
  • History of gastrectomy or bowel resection;
  • Active ongoing fresh hematemesis;
  • Unstable hemodynamics despite adequate resuscitation;
  • Advanced comorbidities (defined as American Society of Anesthesiologists grade 4 or above);
  • Pregnancy.

研究组 & 干预措施

Hemopill

HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.

干预措施: Hemopill

结局指标

主要结局

Area under the ROC curve

时间窗: duration of study, 2 hours

The primary endpoint is the area-under-the-ROC curve (AUC) for HemoPill® capsule, which is defined by the true positive and false positive rates of HI signals.

次要结局

  • Negative predictive value(duration of study, 2 hours)
  • Adverse event rate(duration of study, 2 hours)
  • Positive predictive value(duration of study, 2 hours)
  • Technical success rate(duration of study, 2 hours)
  • Time to a positive HI signal(duration of study, 2 hours)
  • Sensitivity(duration of study, 2 hours)
  • Specificity(duration of study, 2 hours)
  • Time to OGD from Hemopill capsule examination(duration of study, 2 hours)

研究点 (2)

Loading locations...

相似试验